SlideShare una empresa de Scribd logo
1 de 87
Descargar para leer sin conexión
Pulmonary Embolism
Diagnosis and Risk stratification
Mostafa Elshazly, MD
Prof. of pulmonary critical care medicine
Head of PVRU
Kasr Alainy School Of Medicine
Cairo University
Pulmonary embolism
• Acute pulmonary embolism (PE) is a relatively common
disease with an annual rate of 1–2 per 1000 patients [1,
2].
• The clinical presentation of acute PE is nonspecific and
highly variable, ranging from incidentally diagnosed
asymptomatic thrombi to sudden death [3].
1 Naess IA et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 5: 692–9.
2 Silverstein MD, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population based study. Arch Intern Med
1998; 158: 585–93.
3 Stein PD et al. Clinical characteristics of patients with acute pulmonary embolism: data from PIOPED II. Am J Med 2007; 120: 871–9.
• As a result, a clinical suspicion of PE is frequently raised,
whilst the diagnosis is only confirmed in 10–20% of
patients [1,2].
• Diagnostic algorithms have been developed to ensure
reliable and efficient management of patients with
clinically suspected PE
1 Douma RA et al. Performance of 4 clinical decision rules in the diagnostic management of acute pulmonary embolism: a prospective cohort study. Ann
Intern Med 2011; 154: 709–18.
2 van Belle A et al. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and
computed tomography. JAMA 2006; 295: 172–9
• Pulmonary embolism (PE) is a relatively common acute
cardiovascular disorder with high early mortality rates
that, despite advances in diagnosis and treatment over
the past 30 years, have not changed significantly.
J Bĕlohlávek, V dytrych, a linhart. pulmonary embolism, part I. epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation,
diagnosis and nonthrombotic pulmonary embolism. exp clin cardiol 2013;18(2):129-138.
• Once acute PE is diagnosed, prompt initiation of anticoagulant
therapy is indicated to prevent thrombus extension and recurrent
(fatal) PE.
• However, the risk of such an adverse outcome is highly variable,
ranging from <1% to >15% .
1 Aujesky D et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 2005; 172: 1041–6.
• Management decisions including early discharge or prescription
of thrombolytic therapy should preferably be based on
reproducible risk stratification of the individual patient [1, 2].
1 Aujesky D et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 2005; 172: 1041–6.
2 Konstantinides SV et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35: 3033–80
• For the long-term treatment of acute PE, the decision to continue
or stop anticoagulant therapy, after an initial period of 3 months,
depends on the balance between the risk of recurrent venous
thromboembolism (VTE) and of anticoagulant-associated
haemorrhage.
Diagnostic Management Of
Clinically Suspected Acute PE
• Symptoms that may suggest the presence of acute PE are the
sudden onset of dyspnea, pleuritic chest pain, hemoptysis,
extremity swelling suggestive of deep vein thrombosis (DVT) and
syncope [3].
In large diagnostic management studies, the PE prevalence amongst
patients with a clinical suspicion of PE ranged from 10% to 30% .
Integrated approach
• The first step in the diagnostic management of patients with
clinically suspected acute PE is to determine whether the patient
has signs and symptoms of haemodynamic shock.
• If so, patients should be immediately referred for additional
imaging tests and thrombolytic therapy should be started without
waiting for a CDR result or D-dimer level.
Pulmonary embolism
• Pulmonary embolism (PE) is the third cause of mortality
by cardiovascular disease after coronary artery disease
and stroke.
• In Western countries, it remains one of the leading causes
of death in the puerperium and the postoperative period.
Cohen AT, et al; VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism (VTE) in Europe. The number of VTE events and associated
morbidity and mortality. Thromb Haemost 2007;98(4):756–764.
• The incidence of PE is estimated to be approximately 60 to 70
per 100,000, and that of venous thrombosis approximately 124
per 100,000 of the general population (1,2).
1. Oger E. Incidence of venous thromboembolism in a communitybased study in western France. Thromb Haemost 2000;83:657-60.
2. Widimský J, Malý J, Eliáš P, et al. Doporučení pro diagnostiku a léčbu akutní plicní embolie. Vnitř. Lék 2008; 54: 1S25-1S72
J Bĕlohlávek, V dytrych, a linhart. pulmonary embolism, part I. epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation,
diagnosis and nonthrombotic pulmonary embolism. exp clin cardiol 2013;18(2):129-138.
• Nonetheless, PE is difficult to diagnose because of
protean clinical manifestations and poor sensitivity and
specificity of symptoms and signs.
• Nonetheless, PE is difficult to diagnose because of
protean clinical manifestations and poor sensitivity and
specificity of symptoms and signs.
• However, it is still underdiagnosed and up to 80% of PE
found at autopsy have not been suspected ante mortem, a
proportion which has not decreased in the last 30 years.
Stein PD, henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 1995; 108(4):978–981
• However, considerable progress has been made in the workup of
patients with clinically suspected PE, which is based on the
sequential use of pretest clinical probability, plasma D-dimer
measurement, and computed tomography pulmonary
angiography (CTPA).
Pulmonary embolism
• These different diagnostic tests have been used in rational
and cost-effective diagnostic strategies, and the
assessment of clinical probability has been shown to
improve patients’ outcomes.
Roy PM, Meyer G, Vielle B, et al; EMDEPU Study Group. Appropriateness of diagnostic management and outcomes of suspected pulmonary embolism. Ann
Intern Med 2006;144(3):157–164
Pulmonary embolism
• Assessment of PE pretest probability (low, intermediate, or high)
and hemodynamic status is essential to guide additional cost-
effective evaluation and may aid in the interpretation of
subsequent tests.
• Wells
• Geneva
Pulmonary embolism
Well’s Criteria
(Modified And Simplified)
• CHADS
1. Clinical features of DVT 2.Cancer
3. Heart rate > 100/min 4. Hemoptysis
5.Alternative diagnosis less likely
6.DVT/PE in past
7.Surgery in past 4 weeks or immobilization for 3 days
Pulmonary embolism
Pulmonary Embolism Rule-out Criteria
PERC
• Pulmonary embolism can be ruled out clinically if none of the 8
PERC criteria are present in a patient with a low pretest
probability of PE (e.G. Wells PE CPG score of <3) that is
consistent with the ‘gestalt‘ of an experienced physician
Pulmonary Embolism Rule-out Criteria
PERC
1. Age < 50 years 2. Pulse < 100 beats min
3. Sao2 >or= 95% 4. No hemoptysis
5. No estrogen use
6. No surgery/trauma requiring hospitalization within 4 weeks
7. No prior venous thromboembolism (VTE)
8. No unilateral leg swelling
Pulmonary embolism
Pulmonary Embolism Rule-out Criteria
PERC
• HAD CLOTS
1. Hormone 2. Age >50 3. DVT/PE history
4. Coughing blood 5.Leg swelling 6. O2 < 95%
7. Tachycardia 100+ 8. Surgery/trauma <28 days
Pulmonary Embolism Rule-out Criteria
PERC
• What should you do if a patient has a positive d-dimer test, but
on reflection the investigation was not indicated — for example,
the patient meets the PERC rule criteria, which is consistent
with a senior clinician’s ‘gestalt’, but a d-dimer test has already
been performed?
Pulmonary Embolism Rule-out Criteria
PERC
• Ignore the result with respect to assessing VTE risk (go back and
use the Wells criteria for PE!).
• Consider the other possible causes of an elevated D-dimer and
manage as indicated (this may include no further action).
Pulmonary embolism
Pulmonary embolism
Plasma D-dimers
• Plasma D-dimers are the end product of plasmin-mediated fibrin
degradation.
• Plasma D-dimer levels are elevated in the presence of an acute
blood clot because activation of the coagulation system is
associated with simultaneous fibrinolysis activation.
Plasma D-dimers
• Although D-dimers are fibrin specific, fibrin specificity for VTE
is not high because fibrin is also produced under several other
circumstances such as malignancies, inflammation, infection,
necrosis or aortic dissection.
Plasma D-dimers
• Although D-dimers are fibrin specific, fibrin specificity for VTE is not
high because fibrin is also produced under several other
circumstances such as malignancies, inflammation, infection,
necrosis or aortic dissection.
• D-dimer specificity is also limited in elderly patients, pregnant women
and hospitalized individuals.
Plasma D-dimers
• A multicenter, prospective management study evaluated age-adjusted
(age X 10 μg/l, above 50 years) cutoff levels in a cohort of 3,346
patients with suspected PE.
• Using the age-adjusted (instead of the standard 500 mg/l) D-dimer
cutoff increased the number of patients in whom PE could be excluded
from 6.4% to 30% in patients aged 75 years or older, without a
significant increase in the rate of VTE events during follow-up
Righini M, Van Es J, den Exter PL, et al. Ageadjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA 2014;311:1117–24
Factors that can or the accuracy of the d-dimer
assay in diagnosing PE
Factors that can or the accuracy of the d-dimer
assay in diagnosing PE
• False-positive d-dimer
• Cancer and malignancy , Recent surgery , Infection (eg, pneumonia, sepsis)
• Pregnancy , Age > 70 years , Disseminated intravascular coagulation
• Trauma , Arterial thrombosis , Acute coronary syndrome/MI
Pulmonary embolism
CTPA
• In recent years, spiral CTA has become the gold standard for
assessing patients with suspected PE , particularly as a tool
capable of confirming or excluding the presence of thrombi in the
pulmonary bed.
• Advanced multidetector systems require only a short exposure
(approximately 10 s) with the patient holding their breath.
Torbicki A, Perrier A, Konstantidines S, et al. Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2008;29:2276-315
CTPA
• Contra-indications:
• Renal failure
• Pregnancy
• Allergy to radio-contrast
Torbicki A, Perrier A, Konstantidines S, et al. Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2008;29:2276-315
Echocardiography
• Echocardiography, which should be available at all hours in any
intensive care unit, is currently considered – in addition to physical
examination – the main adjunct method of examination in acute PE.
• Echocardiography offers a potential for emergency risk stratification
based on evaluation of the hemodynamic impact of the disease on the
right-heart chambers while also allowing for comprehensive non-
invasive assessment of the patient’s hemodynamic status
Echocardiography
• Echocardiography, which should be available at all hours in any
intensive care unit, is currently considered – in addition to
physical examination – the main adjunct method of examination
in acute PE.
Pulmonary embolism
Pulmonary embolism
Low-risk PE describes normotensive
patients diagnosed with acute
symptomatic PE that have a low
risk for short-term complications
(all-cause mortality, recurrent VTE,
and major bleeding)
Low-risk PE describes normotensive
patients diagnosed with acute
symptomatic PE that have a low
risk for short-term complications
(all-cause mortality, recurrent VTE,
and major bleeding)
Intermediate–high-risk PE describes
confirmed PE, hemodynamic stability,
and a risk of PE-related complications
similar to patients with high-risk PE.
N
M
N
N
Pulmonary embolism
Markers of myocardial injury and overload
• Troponin - released from right ventricle Injury
• Cardiac BNP - released from cardiac myocytes in response to elevated pressures RVD
*A normal troponin and BNP can safely exclude high risk patients with a negative
predictive value of 97-100%
• H-FABP (heart type fatty acid binding protein) – early marker for injury
(good for prognosis as well)
• NGAL (neutrophil gelatinase associated lipocalin) & Cystatin C – both indicating
kidney injury, also shown to have prognostic value
Pulmonary embolism
Assessment of Right Ventricular Dysfunction
Pulmonary embolism
Conclusion
• Pulmonary embolism (PE) remains a major contributor to global
disease burden.
• Risk-adapted treatment and follow-up contributes to a favorable
outcome.
• Age-adjusted cutoff levels increase D-dimer specificity and may
decrease overuse of imaging procedures and overdiagnosis of PE.
Pulmonary embolism
Treatment Of Acute PE
Risk stratification of acute PE
Treatment Of Acute PE
• Patients with acute PE should be stratified according to the short-
term PE-related mortality risk.
• Risk stratification starts with identifying patients in
haemodynamic shock, who are classified as having high-risk or
massive PE with an estimated 30-day PE-related mortality risk of
>15%
Risk stratification of acute PE
Risk stratification of acute PE
Treatment Of Acute PE
Risk stratification of acute PE
Treatment Of Acute PE
Treatment Of Acute PE
Risk stratification of acute PE
• The Hestia decision rule consists of a set of criteria that can be
used to select patients with low-risk PE who are candidates for
early discharge or outpatient treatment.
Treatment Of Acute PE
Risk stratification of acute PE
Treatment Of Acute PE
Risk stratification of acute PE
Management Of High-risk Patients
• Thrombolytic therapy is generally recommended for high-risk
patients with PE with overt Haemodynamic instability without a
high risk of Bleeding complications
Treatment Of Acute PE
Risk stratification of acute PE
Management Of High-risk Patients
• Percutaneous catheter-directed therapy and surgical
embolectomy are alternatives to thrombolytic therapy, for
example in the case of a contraindication to thrombolysis or
after thrombolytic therapy has failed or is deemed inadequate as
first-line treatment
Treatment Of Acute PE
Risk stratification of acute PE
Management Of NonHigh-risk Patients
• Amongst the nonhigh-risk hemodynamically stable patients, two
key questions with regard to therapeutic management remain to
be answered
(i) Do patients with intermediate-risk PE benefit from thrombolytic
therapy?
(ii) Which patients with low risk of adverse outcome are suitable
candidates for outpatient treatment or early discharge?
Treatment Of Acute PE
Risk stratification of acute PE
Management Of NonHigh-risk Patients
Do patients with intermediate-risk PE benefit from
thrombolytic therapy?
Thrombolytic therapy in hemodynamically stable intermediate-risk patients
with PE reduces the risk of the composite endpoint consisting of
haemodynamic deterioration and death at the cost of an increase in the
incidence of major haemorrhage.
Treatment Of Acute PE
Risk stratification of acute PE
Management Of NonHigh-risk Patients
Do patients with intermediate-risk PE benefit from
thrombolytic therapy?
thrombolytic therapy cannot be recommended for
haemodynamically stable intermediate-risk patients with
PE.
Treatment Of Acute PE
Risk stratification of acute PE
Management Of NonHigh-risk Patients
Do patients with intermediate-risk PE benefit from
thrombolytic therapy?
These patients should receive standard anticoagulant
therapy and close monitoring, whilst thrombolytic therapy
should be reserved for patients with haemodynamic
deterioration during the first days of treatment.
Treatment Of Acute PE
Risk stratification of acute PE
Management Of NonHigh-risk Patients
(i) Which patients with low risk of adverse outcome are suitable
candidates for outpatient treatment or early discharge?
In conclusion, it has been shown that outpatient treatment of
patients with PE based on the Hestia decision rule or a
combination of several exclusion criteria and the PESI score is
safe.
Treatment Of Acute PE
Risk stratification of acute PE
Management Of NonHigh-risk Patients
(i) Which patients with low risk of adverse outcome are suitable
candidates for outpatient treatment or early discharge?
The combination of a clinical prediction rule, laboratory
biomarkers and/or findings on imaging tests to further optimize
the identification of patients who can be safely managed in the
outpatient setting remains to be evaluated.
Treatment Of Acute PE
Risk stratification of acute PE
Initial anticoagulant therapy (first 3 months)
Acute PE requires initial treatment with a direct onset
anticoagulant drug to prevent the extension of thrombosis or
fatal recurrent VTE
Treatment Of Acute PE
Risk stratification of acute PE
Initial anticoagulant therapy (first 3 months)
➢Weight-adjusted subcutaneous LMWH is the treatment of choice
for the large majority of patients.
➢IVUH is reserved for patients with
➢Severe renal impairment (creatinine clearance <20–30 mL min1),
➢ Patients with a high risk of haemorrhage including those receiving
thrombolytic therapy, haemodynamically unstable patients and
➢Individuals who are extremely overweight or underweight.
Treatment Of Acute PE
Risk stratification of acute PE
Long-term anticoagulant therapy (after the first 3 months)
Treatment Of Acute PE
Risk stratification of acute PE
Long-term anticoagulant therapy (after the first 3 months)
To determine the optimal duration of treatment after the initial 3
months, the perceived risk of anticoagulant therapy-associated
haemorrhage should be weighed against the risk of recurrent
VTE in every patient individually
Treatment Of Acute PE
Risk stratification of acute PE
Long-term anticoagulant therapy (after the first 3 months)
To determine the optimal duration of treatment after the initial 3
months, the perceived risk of anticoagulant therapy-associated
haemorrhage should be weighed against the risk of recurrent
VTE in every patient individually
Pulmonary embolism
Pulmonary embolism
Pulmonary embolism
Pulmonary embolism
Pulmonary embolism
Pulmonary embolism
Inferior Vena Cava Filters
• Insertion of a temporary or permanent inferior vena cava filter is
another intervention that has been recently studied to assess its
effect on mortality from pulmonary emboli, with preliminarily
favorable results.
Inferior Vena Cava Filters
opatients with contraindications to anticoagulation,
othose who have complications from the use of anticoagulation,
o those who fail to attain adequate anticoagulation while
undergoing treatment.
Symptomatic Subsegmental Pulmonary Embolism
To Treat Or Not
• The use of CTPA is associated with an increase in the incidence
of previously undiagnosed SSPE.
• The clinical relevance of such findings is debated and indirect
evidence suggests that some SSPE might not require
anticoagulant treatment.
Symptomatic Subsegmental Pulmonary Embolism
To Treat Or Not
• In a statement from the Fleischner Society on the management of
suspected acute PE, it is suggested that the clinical relevance of small
peripheral PE and the need to give anticoagulant treatment in such
patients are a matter to debate [28].
• It was also suggested that in patients with small PE and no DVT, the
risks associated with anticoagulant treatment might outweigh the
benefits.
Symptomatic Subsegmental Pulmonary Embolism
To Treat Or Not
• In the meantime, we would suggest:
1) To perform a CTPA only when necessary, i.e. in patients with a
high clinical probability or a positive D-dimer test.
2) If a SSPE is seen on the CTPA, the result should be reviewed with
an expert thoracic radiologist.
Symptomatic Subsegmental Pulmonary Embolism
To Treat Or Not
• In the meantime, we would suggest:
3) In case of SSPE, a bilateral compression US should be performed
and anticoagulant therapy should be given in case of DVT.
4) In the absence of DVT, the decision to treat or not to treat SSPE
should be individualized, taking into account the bleeding risk and
the patients' values and preferences.

Más contenido relacionado

La actualidad más candente

La actualidad más candente (20)

Heart failure - Echocardiography
Heart failure - EchocardiographyHeart failure - Echocardiography
Heart failure - Echocardiography
 
Pulmonaryembolism final
Pulmonaryembolism finalPulmonaryembolism final
Pulmonaryembolism final
 
Eisenmenger syndrome
Eisenmenger syndromeEisenmenger syndrome
Eisenmenger syndrome
 
Pulmonary embolism
Pulmonary embolism Pulmonary embolism
Pulmonary embolism
 
Pulmonary stenosis
Pulmonary stenosisPulmonary stenosis
Pulmonary stenosis
 
Pericardial diseases
Pericardial  diseasesPericardial  diseases
Pericardial diseases
 
Aortic dissection nikku ppt
Aortic dissection nikku pptAortic dissection nikku ppt
Aortic dissection nikku ppt
 
Pulmonary embolism management options
Pulmonary embolism management optionsPulmonary embolism management options
Pulmonary embolism management options
 
SINUS OF VALSALVA ANEURYSM
SINUS OF VALSALVA ANEURYSMSINUS OF VALSALVA ANEURYSM
SINUS OF VALSALVA ANEURYSM
 
Systemic disease involving cardiovascular system
Systemic disease involving cardiovascular systemSystemic disease involving cardiovascular system
Systemic disease involving cardiovascular system
 
Right Ventricular Failure
Right Ventricular FailureRight Ventricular Failure
Right Ventricular Failure
 
Aortic stenosis- Dr Shaz Pamangadan
Aortic stenosis- Dr Shaz PamangadanAortic stenosis- Dr Shaz Pamangadan
Aortic stenosis- Dr Shaz Pamangadan
 
Wpw syndrome
Wpw syndromeWpw syndrome
Wpw syndrome
 
Pulmonary Embolism- Diagnosis by Dr.Tinku Joseph
Pulmonary Embolism- Diagnosis  by Dr.Tinku JosephPulmonary Embolism- Diagnosis  by Dr.Tinku Joseph
Pulmonary Embolism- Diagnosis by Dr.Tinku Joseph
 
Approach to svt
Approach to svt Approach to svt
Approach to svt
 
Pulmonary embolism 21jan21
Pulmonary embolism 21jan21Pulmonary embolism 21jan21
Pulmonary embolism 21jan21
 
PFO CLOSURE
PFO CLOSUREPFO CLOSURE
PFO CLOSURE
 
Long QT Syndrome
Long QT SyndromeLong QT Syndrome
Long QT Syndrome
 
2019 ESC guidelines for pulmonary embolism
2019 ESC guidelines for pulmonary embolism 2019 ESC guidelines for pulmonary embolism
2019 ESC guidelines for pulmonary embolism
 
Restrictive cardiomyopathy
Restrictive cardiomyopathyRestrictive cardiomyopathy
Restrictive cardiomyopathy
 

Similar a Pulmonary embolism

Management of-pulmonary-embolism--a 2016-journal-of-the-american-college-of-
Management of-pulmonary-embolism--a 2016-journal-of-the-american-college-of-Management of-pulmonary-embolism--a 2016-journal-of-the-american-college-of-
Management of-pulmonary-embolism--a 2016-journal-of-the-american-college-of-Pitchya Wangmeesri
 
Pulmonary embolism
Pulmonary embolismPulmonary embolism
Pulmonary embolismvkatbcd
 
Neumonia Adquirida en la Comunidad
Neumonia Adquirida en la ComunidadNeumonia Adquirida en la Comunidad
Neumonia Adquirida en la ComunidadVictor Grau Cuba
 
Update on Pulmonary Embolism
Update on Pulmonary EmbolismUpdate on Pulmonary Embolism
Update on Pulmonary EmbolismMuhanad Majeed
 
VTE assessment and prophylaxis.ppt
VTE assessment and prophylaxis.pptVTE assessment and prophylaxis.ppt
VTE assessment and prophylaxis.pptbenedicta bestari
 
Predictors of prolonged hospital stay in patients with Acute pulmonary thromb...
Predictors of prolonged hospital stay in patients with Acute pulmonary thromb...Predictors of prolonged hospital stay in patients with Acute pulmonary thromb...
Predictors of prolonged hospital stay in patients with Acute pulmonary thromb...DrTapasTripathi
 
dvt prophylaxis, in icu, deep venous thrombosis prophylaxis ,
dvt prophylaxis, in icu, deep venous thrombosis prophylaxis ,dvt prophylaxis, in icu, deep venous thrombosis prophylaxis ,
dvt prophylaxis, in icu, deep venous thrombosis prophylaxis ,gagan brar
 
Acute pulmonary embolism update ESC 2019
Acute pulmonary embolism update ESC 2019Acute pulmonary embolism update ESC 2019
Acute pulmonary embolism update ESC 2019KefelegnDejene
 
Pumonary embolism vkas
Pumonary embolism vkasPumonary embolism vkas
Pumonary embolism vkasVkas Subedi
 
Pulmonary Embolism lecture 2022
Pulmonary Embolism lecture 2022Pulmonary Embolism lecture 2022
Pulmonary Embolism lecture 2022Dr.Marwan Sneymeh
 
escpe1-191229130329.pptx
escpe1-191229130329.pptxescpe1-191229130329.pptx
escpe1-191229130329.pptxEastmaMeili1
 
pulmonary embolism.pptx
pulmonary embolism.pptxpulmonary embolism.pptx
pulmonary embolism.pptxghadeereideh
 
Rheumatic Heart disease
Rheumatic Heart disease Rheumatic Heart disease
Rheumatic Heart disease RakhiYadav53
 
Role of DVT surveillance in TBI/SCI
Role of DVT surveillance in TBI/SCIRole of DVT surveillance in TBI/SCI
Role of DVT surveillance in TBI/SCIAmit Agrawal
 
Risk factors of Acute Coronary Syndrome at Prince Ali Bin Alhussein hospital
Risk factors of Acute Coronary Syndrome at Prince Ali Bin Alhussein hospitalRisk factors of Acute Coronary Syndrome at Prince Ali Bin Alhussein hospital
Risk factors of Acute Coronary Syndrome at Prince Ali Bin Alhussein hospitalMinistry of Health
 

Similar a Pulmonary embolism (20)

Management of-pulmonary-embolism--a 2016-journal-of-the-american-college-of-
Management of-pulmonary-embolism--a 2016-journal-of-the-american-college-of-Management of-pulmonary-embolism--a 2016-journal-of-the-american-college-of-
Management of-pulmonary-embolism--a 2016-journal-of-the-american-college-of-
 
Pulmonary embolism
Pulmonary embolismPulmonary embolism
Pulmonary embolism
 
Pulmonary embolism
Pulmonary embolismPulmonary embolism
Pulmonary embolism
 
Neumonia Adquirida en la Comunidad
Neumonia Adquirida en la ComunidadNeumonia Adquirida en la Comunidad
Neumonia Adquirida en la Comunidad
 
Update on Pulmonary Embolism
Update on Pulmonary EmbolismUpdate on Pulmonary Embolism
Update on Pulmonary Embolism
 
VTE assessment and prophylaxis.ppt
VTE assessment and prophylaxis.pptVTE assessment and prophylaxis.ppt
VTE assessment and prophylaxis.ppt
 
Predictors of prolonged hospital stay in patients with Acute pulmonary thromb...
Predictors of prolonged hospital stay in patients with Acute pulmonary thromb...Predictors of prolonged hospital stay in patients with Acute pulmonary thromb...
Predictors of prolonged hospital stay in patients with Acute pulmonary thromb...
 
dvt prophylaxis, in icu, deep venous thrombosis prophylaxis ,
dvt prophylaxis, in icu, deep venous thrombosis prophylaxis ,dvt prophylaxis, in icu, deep venous thrombosis prophylaxis ,
dvt prophylaxis, in icu, deep venous thrombosis prophylaxis ,
 
Acute pulmonary embolism update ESC 2019
Acute pulmonary embolism update ESC 2019Acute pulmonary embolism update ESC 2019
Acute pulmonary embolism update ESC 2019
 
Pumonary embolism vkas
Pumonary embolism vkasPumonary embolism vkas
Pumonary embolism vkas
 
pe.pptx
pe.pptxpe.pptx
pe.pptx
 
Austin Journal of Clinical Cardiology
Austin Journal of Clinical CardiologyAustin Journal of Clinical Cardiology
Austin Journal of Clinical Cardiology
 
Pulmonary Embolism lecture 2022
Pulmonary Embolism lecture 2022Pulmonary Embolism lecture 2022
Pulmonary Embolism lecture 2022
 
escpe1-191229130329.pptx
escpe1-191229130329.pptxescpe1-191229130329.pptx
escpe1-191229130329.pptx
 
pulmonary embolism.pptx
pulmonary embolism.pptxpulmonary embolism.pptx
pulmonary embolism.pptx
 
Pulmonary Embolism.pptx
Pulmonary Embolism.pptxPulmonary Embolism.pptx
Pulmonary Embolism.pptx
 
EarlyCDT-Lung
EarlyCDT-LungEarlyCDT-Lung
EarlyCDT-Lung
 
Rheumatic Heart disease
Rheumatic Heart disease Rheumatic Heart disease
Rheumatic Heart disease
 
Role of DVT surveillance in TBI/SCI
Role of DVT surveillance in TBI/SCIRole of DVT surveillance in TBI/SCI
Role of DVT surveillance in TBI/SCI
 
Risk factors of Acute Coronary Syndrome at Prince Ali Bin Alhussein hospital
Risk factors of Acute Coronary Syndrome at Prince Ali Bin Alhussein hospitalRisk factors of Acute Coronary Syndrome at Prince Ali Bin Alhussein hospital
Risk factors of Acute Coronary Syndrome at Prince Ali Bin Alhussein hospital
 

Más de Mostafa Elshazly

Monitoring during noninvasive ventilation
Monitoring during noninvasive ventilationMonitoring during noninvasive ventilation
Monitoring during noninvasive ventilationMostafa Elshazly
 
Weaning, extubation and decannulation
Weaning, extubation and decannulationWeaning, extubation and decannulation
Weaning, extubation and decannulationMostafa Elshazly
 
Patient ventilator interactions
Patient ventilator interactionsPatient ventilator interactions
Patient ventilator interactionsMostafa Elshazly
 
Smoking related interstitial lung diseases
Smoking related interstitial lung diseasesSmoking related interstitial lung diseases
Smoking related interstitial lung diseasesMostafa Elshazly
 

Más de Mostafa Elshazly (7)

Niv ventilatory modes
Niv ventilatory modesNiv ventilatory modes
Niv ventilatory modes
 
Niv and weaning
Niv and weaningNiv and weaning
Niv and weaning
 
Monitoring during noninvasive ventilation
Monitoring during noninvasive ventilationMonitoring during noninvasive ventilation
Monitoring during noninvasive ventilation
 
Weaning, extubation and decannulation
Weaning, extubation and decannulationWeaning, extubation and decannulation
Weaning, extubation and decannulation
 
Patient ventilator interactions
Patient ventilator interactionsPatient ventilator interactions
Patient ventilator interactions
 
Basic modes of mv
Basic modes of mvBasic modes of mv
Basic modes of mv
 
Smoking related interstitial lung diseases
Smoking related interstitial lung diseasesSmoking related interstitial lung diseases
Smoking related interstitial lung diseases
 

Último

SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 

Último (20)

SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 

Pulmonary embolism

  • 1. Pulmonary Embolism Diagnosis and Risk stratification Mostafa Elshazly, MD Prof. of pulmonary critical care medicine Head of PVRU Kasr Alainy School Of Medicine Cairo University
  • 3. • Acute pulmonary embolism (PE) is a relatively common disease with an annual rate of 1–2 per 1000 patients [1, 2]. • The clinical presentation of acute PE is nonspecific and highly variable, ranging from incidentally diagnosed asymptomatic thrombi to sudden death [3]. 1 Naess IA et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 5: 692–9. 2 Silverstein MD, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population based study. Arch Intern Med 1998; 158: 585–93. 3 Stein PD et al. Clinical characteristics of patients with acute pulmonary embolism: data from PIOPED II. Am J Med 2007; 120: 871–9.
  • 4. • As a result, a clinical suspicion of PE is frequently raised, whilst the diagnosis is only confirmed in 10–20% of patients [1,2]. • Diagnostic algorithms have been developed to ensure reliable and efficient management of patients with clinically suspected PE 1 Douma RA et al. Performance of 4 clinical decision rules in the diagnostic management of acute pulmonary embolism: a prospective cohort study. Ann Intern Med 2011; 154: 709–18. 2 van Belle A et al. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA 2006; 295: 172–9
  • 5. • Pulmonary embolism (PE) is a relatively common acute cardiovascular disorder with high early mortality rates that, despite advances in diagnosis and treatment over the past 30 years, have not changed significantly. J Bĕlohlávek, V dytrych, a linhart. pulmonary embolism, part I. epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic pulmonary embolism. exp clin cardiol 2013;18(2):129-138.
  • 6. • Once acute PE is diagnosed, prompt initiation of anticoagulant therapy is indicated to prevent thrombus extension and recurrent (fatal) PE. • However, the risk of such an adverse outcome is highly variable, ranging from <1% to >15% . 1 Aujesky D et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 2005; 172: 1041–6.
  • 7. • Management decisions including early discharge or prescription of thrombolytic therapy should preferably be based on reproducible risk stratification of the individual patient [1, 2]. 1 Aujesky D et al. Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med 2005; 172: 1041–6. 2 Konstantinides SV et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35: 3033–80
  • 8. • For the long-term treatment of acute PE, the decision to continue or stop anticoagulant therapy, after an initial period of 3 months, depends on the balance between the risk of recurrent venous thromboembolism (VTE) and of anticoagulant-associated haemorrhage.
  • 9. Diagnostic Management Of Clinically Suspected Acute PE • Symptoms that may suggest the presence of acute PE are the sudden onset of dyspnea, pleuritic chest pain, hemoptysis, extremity swelling suggestive of deep vein thrombosis (DVT) and syncope [3]. In large diagnostic management studies, the PE prevalence amongst patients with a clinical suspicion of PE ranged from 10% to 30% .
  • 10. Integrated approach • The first step in the diagnostic management of patients with clinically suspected acute PE is to determine whether the patient has signs and symptoms of haemodynamic shock. • If so, patients should be immediately referred for additional imaging tests and thrombolytic therapy should be started without waiting for a CDR result or D-dimer level.
  • 12. • Pulmonary embolism (PE) is the third cause of mortality by cardiovascular disease after coronary artery disease and stroke. • In Western countries, it remains one of the leading causes of death in the puerperium and the postoperative period. Cohen AT, et al; VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007;98(4):756–764.
  • 13. • The incidence of PE is estimated to be approximately 60 to 70 per 100,000, and that of venous thrombosis approximately 124 per 100,000 of the general population (1,2). 1. Oger E. Incidence of venous thromboembolism in a communitybased study in western France. Thromb Haemost 2000;83:657-60. 2. Widimský J, Malý J, Eliáš P, et al. Doporučení pro diagnostiku a léčbu akutní plicní embolie. Vnitř. Lék 2008; 54: 1S25-1S72
  • 14. J Bĕlohlávek, V dytrych, a linhart. pulmonary embolism, part I. epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic pulmonary embolism. exp clin cardiol 2013;18(2):129-138.
  • 15. • Nonetheless, PE is difficult to diagnose because of protean clinical manifestations and poor sensitivity and specificity of symptoms and signs.
  • 16. • Nonetheless, PE is difficult to diagnose because of protean clinical manifestations and poor sensitivity and specificity of symptoms and signs.
  • 17. • However, it is still underdiagnosed and up to 80% of PE found at autopsy have not been suspected ante mortem, a proportion which has not decreased in the last 30 years. Stein PD, henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 1995; 108(4):978–981
  • 18. • However, considerable progress has been made in the workup of patients with clinically suspected PE, which is based on the sequential use of pretest clinical probability, plasma D-dimer measurement, and computed tomography pulmonary angiography (CTPA).
  • 20. • These different diagnostic tests have been used in rational and cost-effective diagnostic strategies, and the assessment of clinical probability has been shown to improve patients’ outcomes. Roy PM, Meyer G, Vielle B, et al; EMDEPU Study Group. Appropriateness of diagnostic management and outcomes of suspected pulmonary embolism. Ann Intern Med 2006;144(3):157–164
  • 22. • Assessment of PE pretest probability (low, intermediate, or high) and hemodynamic status is essential to guide additional cost- effective evaluation and may aid in the interpretation of subsequent tests. • Wells • Geneva
  • 24. Well’s Criteria (Modified And Simplified) • CHADS 1. Clinical features of DVT 2.Cancer 3. Heart rate > 100/min 4. Hemoptysis 5.Alternative diagnosis less likely 6.DVT/PE in past 7.Surgery in past 4 weeks or immobilization for 3 days
  • 26. Pulmonary Embolism Rule-out Criteria PERC • Pulmonary embolism can be ruled out clinically if none of the 8 PERC criteria are present in a patient with a low pretest probability of PE (e.G. Wells PE CPG score of <3) that is consistent with the ‘gestalt‘ of an experienced physician
  • 27. Pulmonary Embolism Rule-out Criteria PERC 1. Age < 50 years 2. Pulse < 100 beats min 3. Sao2 >or= 95% 4. No hemoptysis 5. No estrogen use 6. No surgery/trauma requiring hospitalization within 4 weeks 7. No prior venous thromboembolism (VTE) 8. No unilateral leg swelling
  • 29. Pulmonary Embolism Rule-out Criteria PERC • HAD CLOTS 1. Hormone 2. Age >50 3. DVT/PE history 4. Coughing blood 5.Leg swelling 6. O2 < 95% 7. Tachycardia 100+ 8. Surgery/trauma <28 days
  • 30. Pulmonary Embolism Rule-out Criteria PERC • What should you do if a patient has a positive d-dimer test, but on reflection the investigation was not indicated — for example, the patient meets the PERC rule criteria, which is consistent with a senior clinician’s ‘gestalt’, but a d-dimer test has already been performed?
  • 31. Pulmonary Embolism Rule-out Criteria PERC • Ignore the result with respect to assessing VTE risk (go back and use the Wells criteria for PE!). • Consider the other possible causes of an elevated D-dimer and manage as indicated (this may include no further action).
  • 34. Plasma D-dimers • Plasma D-dimers are the end product of plasmin-mediated fibrin degradation. • Plasma D-dimer levels are elevated in the presence of an acute blood clot because activation of the coagulation system is associated with simultaneous fibrinolysis activation.
  • 35. Plasma D-dimers • Although D-dimers are fibrin specific, fibrin specificity for VTE is not high because fibrin is also produced under several other circumstances such as malignancies, inflammation, infection, necrosis or aortic dissection.
  • 36. Plasma D-dimers • Although D-dimers are fibrin specific, fibrin specificity for VTE is not high because fibrin is also produced under several other circumstances such as malignancies, inflammation, infection, necrosis or aortic dissection. • D-dimer specificity is also limited in elderly patients, pregnant women and hospitalized individuals.
  • 37. Plasma D-dimers • A multicenter, prospective management study evaluated age-adjusted (age X 10 μg/l, above 50 years) cutoff levels in a cohort of 3,346 patients with suspected PE. • Using the age-adjusted (instead of the standard 500 mg/l) D-dimer cutoff increased the number of patients in whom PE could be excluded from 6.4% to 30% in patients aged 75 years or older, without a significant increase in the rate of VTE events during follow-up Righini M, Van Es J, den Exter PL, et al. Ageadjusted D-dimer cutoff levels to rule out pulmonary embolism: the ADJUST-PE study. JAMA 2014;311:1117–24
  • 38. Factors that can or the accuracy of the d-dimer assay in diagnosing PE
  • 39. Factors that can or the accuracy of the d-dimer assay in diagnosing PE • False-positive d-dimer • Cancer and malignancy , Recent surgery , Infection (eg, pneumonia, sepsis) • Pregnancy , Age > 70 years , Disseminated intravascular coagulation • Trauma , Arterial thrombosis , Acute coronary syndrome/MI
  • 41. CTPA • In recent years, spiral CTA has become the gold standard for assessing patients with suspected PE , particularly as a tool capable of confirming or excluding the presence of thrombi in the pulmonary bed. • Advanced multidetector systems require only a short exposure (approximately 10 s) with the patient holding their breath. Torbicki A, Perrier A, Konstantidines S, et al. Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2008;29:2276-315
  • 42. CTPA • Contra-indications: • Renal failure • Pregnancy • Allergy to radio-contrast Torbicki A, Perrier A, Konstantidines S, et al. Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2008;29:2276-315
  • 43. Echocardiography • Echocardiography, which should be available at all hours in any intensive care unit, is currently considered – in addition to physical examination – the main adjunct method of examination in acute PE. • Echocardiography offers a potential for emergency risk stratification based on evaluation of the hemodynamic impact of the disease on the right-heart chambers while also allowing for comprehensive non- invasive assessment of the patient’s hemodynamic status
  • 44. Echocardiography • Echocardiography, which should be available at all hours in any intensive care unit, is currently considered – in addition to physical examination – the main adjunct method of examination in acute PE.
  • 47. Low-risk PE describes normotensive patients diagnosed with acute symptomatic PE that have a low risk for short-term complications (all-cause mortality, recurrent VTE, and major bleeding)
  • 48. Low-risk PE describes normotensive patients diagnosed with acute symptomatic PE that have a low risk for short-term complications (all-cause mortality, recurrent VTE, and major bleeding) Intermediate–high-risk PE describes confirmed PE, hemodynamic stability, and a risk of PE-related complications similar to patients with high-risk PE. N M N N
  • 50. Markers of myocardial injury and overload • Troponin - released from right ventricle Injury • Cardiac BNP - released from cardiac myocytes in response to elevated pressures RVD *A normal troponin and BNP can safely exclude high risk patients with a negative predictive value of 97-100% • H-FABP (heart type fatty acid binding protein) – early marker for injury (good for prognosis as well) • NGAL (neutrophil gelatinase associated lipocalin) & Cystatin C – both indicating kidney injury, also shown to have prognostic value
  • 52. Assessment of Right Ventricular Dysfunction
  • 55. • Pulmonary embolism (PE) remains a major contributor to global disease burden. • Risk-adapted treatment and follow-up contributes to a favorable outcome. • Age-adjusted cutoff levels increase D-dimer specificity and may decrease overuse of imaging procedures and overdiagnosis of PE.
  • 57. Treatment Of Acute PE Risk stratification of acute PE
  • 58. Treatment Of Acute PE • Patients with acute PE should be stratified according to the short- term PE-related mortality risk. • Risk stratification starts with identifying patients in haemodynamic shock, who are classified as having high-risk or massive PE with an estimated 30-day PE-related mortality risk of >15% Risk stratification of acute PE
  • 59. Risk stratification of acute PE Treatment Of Acute PE
  • 60. Risk stratification of acute PE Treatment Of Acute PE
  • 61. Treatment Of Acute PE Risk stratification of acute PE • The Hestia decision rule consists of a set of criteria that can be used to select patients with low-risk PE who are candidates for early discharge or outpatient treatment.
  • 62. Treatment Of Acute PE Risk stratification of acute PE
  • 63. Treatment Of Acute PE Risk stratification of acute PE Management Of High-risk Patients • Thrombolytic therapy is generally recommended for high-risk patients with PE with overt Haemodynamic instability without a high risk of Bleeding complications
  • 64. Treatment Of Acute PE Risk stratification of acute PE Management Of High-risk Patients • Percutaneous catheter-directed therapy and surgical embolectomy are alternatives to thrombolytic therapy, for example in the case of a contraindication to thrombolysis or after thrombolytic therapy has failed or is deemed inadequate as first-line treatment
  • 65. Treatment Of Acute PE Risk stratification of acute PE Management Of NonHigh-risk Patients • Amongst the nonhigh-risk hemodynamically stable patients, two key questions with regard to therapeutic management remain to be answered (i) Do patients with intermediate-risk PE benefit from thrombolytic therapy? (ii) Which patients with low risk of adverse outcome are suitable candidates for outpatient treatment or early discharge?
  • 66. Treatment Of Acute PE Risk stratification of acute PE Management Of NonHigh-risk Patients Do patients with intermediate-risk PE benefit from thrombolytic therapy? Thrombolytic therapy in hemodynamically stable intermediate-risk patients with PE reduces the risk of the composite endpoint consisting of haemodynamic deterioration and death at the cost of an increase in the incidence of major haemorrhage.
  • 67. Treatment Of Acute PE Risk stratification of acute PE Management Of NonHigh-risk Patients Do patients with intermediate-risk PE benefit from thrombolytic therapy? thrombolytic therapy cannot be recommended for haemodynamically stable intermediate-risk patients with PE.
  • 68. Treatment Of Acute PE Risk stratification of acute PE Management Of NonHigh-risk Patients Do patients with intermediate-risk PE benefit from thrombolytic therapy? These patients should receive standard anticoagulant therapy and close monitoring, whilst thrombolytic therapy should be reserved for patients with haemodynamic deterioration during the first days of treatment.
  • 69. Treatment Of Acute PE Risk stratification of acute PE Management Of NonHigh-risk Patients (i) Which patients with low risk of adverse outcome are suitable candidates for outpatient treatment or early discharge? In conclusion, it has been shown that outpatient treatment of patients with PE based on the Hestia decision rule or a combination of several exclusion criteria and the PESI score is safe.
  • 70. Treatment Of Acute PE Risk stratification of acute PE Management Of NonHigh-risk Patients (i) Which patients with low risk of adverse outcome are suitable candidates for outpatient treatment or early discharge? The combination of a clinical prediction rule, laboratory biomarkers and/or findings on imaging tests to further optimize the identification of patients who can be safely managed in the outpatient setting remains to be evaluated.
  • 71. Treatment Of Acute PE Risk stratification of acute PE Initial anticoagulant therapy (first 3 months) Acute PE requires initial treatment with a direct onset anticoagulant drug to prevent the extension of thrombosis or fatal recurrent VTE
  • 72. Treatment Of Acute PE Risk stratification of acute PE Initial anticoagulant therapy (first 3 months) ➢Weight-adjusted subcutaneous LMWH is the treatment of choice for the large majority of patients. ➢IVUH is reserved for patients with ➢Severe renal impairment (creatinine clearance <20–30 mL min1), ➢ Patients with a high risk of haemorrhage including those receiving thrombolytic therapy, haemodynamically unstable patients and ➢Individuals who are extremely overweight or underweight.
  • 73. Treatment Of Acute PE Risk stratification of acute PE Long-term anticoagulant therapy (after the first 3 months)
  • 74. Treatment Of Acute PE Risk stratification of acute PE Long-term anticoagulant therapy (after the first 3 months) To determine the optimal duration of treatment after the initial 3 months, the perceived risk of anticoagulant therapy-associated haemorrhage should be weighed against the risk of recurrent VTE in every patient individually
  • 75. Treatment Of Acute PE Risk stratification of acute PE Long-term anticoagulant therapy (after the first 3 months) To determine the optimal duration of treatment after the initial 3 months, the perceived risk of anticoagulant therapy-associated haemorrhage should be weighed against the risk of recurrent VTE in every patient individually
  • 82. Inferior Vena Cava Filters • Insertion of a temporary or permanent inferior vena cava filter is another intervention that has been recently studied to assess its effect on mortality from pulmonary emboli, with preliminarily favorable results.
  • 83. Inferior Vena Cava Filters opatients with contraindications to anticoagulation, othose who have complications from the use of anticoagulation, o those who fail to attain adequate anticoagulation while undergoing treatment.
  • 84. Symptomatic Subsegmental Pulmonary Embolism To Treat Or Not • The use of CTPA is associated with an increase in the incidence of previously undiagnosed SSPE. • The clinical relevance of such findings is debated and indirect evidence suggests that some SSPE might not require anticoagulant treatment.
  • 85. Symptomatic Subsegmental Pulmonary Embolism To Treat Or Not • In a statement from the Fleischner Society on the management of suspected acute PE, it is suggested that the clinical relevance of small peripheral PE and the need to give anticoagulant treatment in such patients are a matter to debate [28]. • It was also suggested that in patients with small PE and no DVT, the risks associated with anticoagulant treatment might outweigh the benefits.
  • 86. Symptomatic Subsegmental Pulmonary Embolism To Treat Or Not • In the meantime, we would suggest: 1) To perform a CTPA only when necessary, i.e. in patients with a high clinical probability or a positive D-dimer test. 2) If a SSPE is seen on the CTPA, the result should be reviewed with an expert thoracic radiologist.
  • 87. Symptomatic Subsegmental Pulmonary Embolism To Treat Or Not • In the meantime, we would suggest: 3) In case of SSPE, a bilateral compression US should be performed and anticoagulant therapy should be given in case of DVT. 4) In the absence of DVT, the decision to treat or not to treat SSPE should be individualized, taking into account the bleeding risk and the patients' values and preferences.